DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Citigroup Upgrades Vanda Pharmaceuticals to Buy, Announces $14 Price Target

Citigroup analyst Joel Beatty upgrades Vanda Pharmaceuticals (NASDAQ:VNDA) from Neutral to Buy and announces $14 price target.

Benzinga · 03/12/2020 09:44

Citigroup analyst Joel Beatty upgrades Vanda Pharmaceuticals (NASDAQ:VNDA) from Neutral to Buy and announces $14 price target.